حول Summit Therapeutics Sub
Summit is committed to leadership in resolving serious, unmet medical needs in oncology for the betterment of overall HUMAN HEALTH. Stifel Fireside Chat Patients & Caregivers Summit Latest News Committed to Optimizing Human Health Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly
60 فرصة عمل في Summit Therapeutics Sub
**THIS POSITION WILL BE ON-SITE AT OUR MIAMI FL OFFICE or MENLO PARK CA OFFICE**About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesi المزيد...
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Senior Director, Cmc Strategy Development & Delivery
221000 - 277000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Director, Accounting
184000 - 230000
LOCATION: Position will be on-site in Menlo Park CA or Princeton NJAbout Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associa المزيد...
Director, Quality Assurance
186000 - 233000
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays u المزيد...
Accounting Manager, R&d
118500 - 139500
Job Title: Accounting Manager R&DDepartment: FinanceLocation: Menlo Park CA ONSITEJob Type: Full-Time ACCOUNTING MANAGER R&D About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy المزيد...
Associate Director, Clinical Operations
168500 - 198500
Location: On-Site 4 days per week at ourMenlo Park CA Princeton NJ or Miami FL officeAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis المزيد...
Therapeutic Area Head, Clinical Development
344000 - 430000
*This position will be located on-site in Menlo Park CA / Princeton NJ / or Miami FLAbout Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesi المزيد...
Manager, Clinical Study Start Up (contract)
50 - 60
*THIS IS A TEMPORARY POSITION*About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single المزيد...
Sr. Director, Clinical Operations, Europe
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Svp, Us Marketing
400000 - 430000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Vice President, Global Marketing
300000 - 350000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Manager, Clinical Data Management
135000 - 155000
Location: On-Site 4 days per week at our Menlo Park CA Princeton NJ or Miami FL office.About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogen المزيد...
THIS POSITION WILL BE ON-SITE IN ONE OF THE FOLLOWING LOCATIONS: San Francisco Bay Area / Miami FL / Princeton New JerseyCORPORATE COUNSEL CONTRACTS Overview of Role: The Corporate Counsel Contracts is responsible for supporting the review negotiation and execution of critical compan المزيد...
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Manager, Financial Planning & Analysis (r&d)
118000 - 140000
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab display المزيد...
About Summit: Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays المزيد...
Manager, Upstream Msat
120000 - 140000
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays u المزيد...
Manager, Downstream Msat
120000 - 140000
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays u المزيد...
About Summit:Ivonescimab known as SMT112 is a novel potential first-in-class investigationalbispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays u المزيد...
